Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atreca, Inc.BCEL · Entity 91940 | Director | June 13, 2023 | June 15, 2023 |
| CERO THERAPEUTICS HOLDINGS, INC.CERO · Entity 8622 | Director | January 07, 2026 | January 09, 2026 |
| Clovis Oncology, Inc.CLVS · Entity 122635 | Director | June 10, 2021 | June 11, 2021 |
| Launch One Acquisition Corp.LPAA · Entity 6908 | Director | July 11, 2024 | July 11, 2024 |
| PHASERX, INC.PZRX · Entity 174777 | Director · 10% owner | May 25, 2017 | May 30, 2017 |
| eFFECTOR Therapeutics, Inc.LWAC · Entity 89916 | Director | January 12, 2021 | January 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atreca, Inc.
Report date June 13, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2023-06-12 | Direct | 12,000 |
Reported balance
After 2023-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-13 · Grant · Acquired 12,000 · Balance 12,000 F1: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control.
CERO THERAPEUTICS HOLDINGS, INC.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2036-01-06 | Direct | 1,612,099 |
Reported balance
After 2026-01-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 1,612,099 · Balance 1,612,099 |
Clovis Oncology, Inc.
Report date June 10, 2021 · Filed June 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.97 · Expires 2031-06-10 | Direct | 42,223 |
Reported balance
After 2021-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-10 · Grant · Acquired 42,223 · Balance 42,223 F1: The options shall vest on the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The options shall vest on the one-year anniversary of the date of grant.
Launch One Acquisition Corp.
Report date July 11, 2024 · Filed July 11, 2024
This filing explicitly reported no securities owned.
PHASERX, INC.
Report date May 25, 2017 · Filed May 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 · Expires 2027-05-25 | Direct | 14,000 |
Reported balance
After 2017-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-25 · Grant · Acquired 14,000 · Balance 14,000 F1: On May 25, 2017, the reporting person was granted an option to purchase shares of common stock. The option vests in 1/12th equal installments on each monthly anniversary of May 25, 2017, and subject to the reporting person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 25, 2017, the reporting person was granted an option to purchase shares of common stock. The option vests in 1/12th equal installments on each monthly anniversary of May 25, 2017, and subject to the reporting person's continued service to the Issuer.
eFFECTOR Therapeutics, Inc.
Report date January 12, 2021 · Filed January 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | IndirectBy LWAC D&O LLC | 25,000 |
Reported balance
After 2021-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-12 · Other · Disposed 25,000 · Balance 25,000 F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date. F2: Allocated to the reporting person as a member of LWAC D&O LLC, a member of Locust Walk Sponsor, LLC, for service on the issuer's board of directors. F3: The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date.
F2: Allocated to the reporting person as a member of LWAC D&O LLC, a member of Locust Walk Sponsor, LLC, for service on the issuer's board of directors.
F3: The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2017 Filed Jun 28, 2017 18:53 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | OtherCommon Stock | 4,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-042168 · a4.xml · nonDerivative · entry 2 ATWOOD BRIAN G · CIK 0001266567 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 25,577 F3 · kind: Represents a change in the form of ownership by virtue of the receipt of shares in the pro-rata distribution of Common Stock of the Issuer by Versant Ventures IV, LLC without consideration to its members. F2 · ownership.nature: The shares are held by the Atwood-Edminster Trust dated 4/2/2000 (the "Trust"). Brian G. Atwood (the "Reporting Person") is a trustee and a named beneficiary of the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 18:53 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | OtherCommon Stock | 212 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-042168 · a4.xml · nonDerivative · entry 1 ATWOOD BRIAN G · CIK 0001266567 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 20,579 F1 · kind: Represents a change in the form of ownership by virtue of the receipt of shares in the pro-rata distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. without consideration to its partners. F2 · ownership.nature: The shares are held by the Atwood-Edminster Trust dated 4/2/2000 (the "Trust"). Brian G. Atwood (the "Reporting Person") is a trustee and a named beneficiary of the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| June 08, 2017 Filed Jun 8, 2017 17:42 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $59.56 | $0.00 |
DisclosureSEC source: 0000899243-17-015812 · doc4.xml · derivative · entry 1 ATWOOD BRIAN G · CIK 0001266567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-08 F1 · derivative.exercise_date: One-twelfth (1/12) of the shares subject to the option shall vest on each of the first twelve (12) monthly anniversaries of the date of grant. Read SEC document |
| May 25, 2017 Filed May 30, 2017 17:49 UTC | PHASERX, INC. PZRX · Entity 174777 | GrantEmployee Stock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001144204-17-030196 · v468058_form4.xml · derivative · entry 1 ATWOOD BRIAN G · CIK 0001266567 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-05-25 F1 · derivative.exercise_date: On May 25, 2017, the reporting person was granted an option to purchase shares of common stock. The option vests in 1/12th equal installments on each monthly anniversary of May 25, 2017, and subject to the reporting person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.